INTRODUCTION: There are limited data comparing long-term efficacy and safety of OPTIMA tacrolimus-eluting stent (TES) with Dual Antiplatelet Therapy (DAT) in daily practice. Therefore, we evaluated the safety and performance of OPTIMA TES with 2 or 6-month dual antiplatelet therapy in a 12-month follow up period. METHODS: In a prospective, non-randomized single center registry in which 106 patients that underwent percutaneous coronary intervention with the OPTIMA TES between January 2010 and February 2011 were enrolled. After stenting, 62 patients received DAT for 2 months and the remainder for 6 months. Major Adverse Cardiac Events (MACE), stent thrombosis rate and target lesion revascularization (TLR) were evaluated in a 12-month follow-up period for 2-and 6-month DAT groups. RESULTS: No cases with death, MI or stent thrombosis were observed within the 12-month follow-up period in either of the groups. TLR and MACE rates were higher in 6-month DAT group compared to 2-month group (6.8% vs. 3.2% respectively, P=0.001) which may be due to this group having more diffuse disease (23.60±5.69 vs. 20.88±5.14, P=0.018). CONCLUSION:OPTIMA tacrolimus-eluting stent is safe and efficient with short term DAT period. A randomized trial is needed for better evaluations of OPTIMA TES in daily clinical practice.
RCT Entities:
INTRODUCTION: There are limited data comparing long-term efficacy and safety of OPTIMA tacrolimus-eluting stent (TES) with Dual Antiplatelet Therapy (DAT) in daily practice. Therefore, we evaluated the safety and performance of OPTIMA TES with 2 or 6-month dual antiplatelet therapy in a 12-month follow up period. METHODS: In a prospective, non-randomized single center registry in which 106 patients that underwent percutaneous coronary intervention with the OPTIMA TES between January 2010 and February 2011 were enrolled. After stenting, 62 patients received DAT for 2 months and the remainder for 6 months. Major Adverse Cardiac Events (MACE), stent thrombosis rate and target lesion revascularization (TLR) were evaluated in a 12-month follow-up period for 2-and 6-month DAT groups. RESULTS: No cases with death, MI or stent thrombosis were observed within the 12-month follow-up period in either of the groups. TLR and MACE rates were higher in 6-month DAT group compared to 2-month group (6.8% vs. 3.2% respectively, P=0.001) which may be due to this group having more diffuse disease (23.60±5.69 vs. 20.88±5.14, P=0.018). CONCLUSION:OPTIMA tacrolimus-eluting stent is safe and efficient with short term DAT period. A randomized trial is needed for better evaluations of OPTIMA TES in daily clinical practice.
Authors: Antonio L Bartorelli; Daniela Trabattoni; Franco Fabbiocchi; Piero Montorsi; Stefano de Martini; Giuseppe Calligaris; Giovanni Teruzzi; Stefano Galli; Paolo Ravagnani Journal: J Interv Cardiol Date: 2003-12 Impact factor: 2.279
Authors: Michael Joner; Aloke V Finn; Andrew Farb; Erik K Mont; Frank D Kolodgie; Elena Ladich; Robert Kutys; Kristi Skorija; Herman K Gold; Renu Virmani Journal: J Am Coll Cardiol Date: 2006-05-05 Impact factor: 24.094
Authors: David E Kandzari; Dominick J Angiolillo; Matthew J Price; Paul S Teirstein Journal: JACC Cardiovasc Interv Date: 2009-12 Impact factor: 11.195
Authors: Salvatore Cassese; Giuseppe De Luca; Bruno Villari; Sergio Berti; Pietro Bellone; Alfonso Alfieri; Antonio Montinaro; Gaetano Quaranta; Paolo Marraccini; Federico Piscione Journal: Catheter Cardiovasc Interv Date: 2011-11-09 Impact factor: 2.692
Authors: Marie-Claude Morice; Hans-Peter Bestehorn; Didier Carrié; Carlos Macaya; Wim Aengevaeren; William Wijns; Christophe Dubois; Robert de Winter; Stefan Verheye; Stefan Hoffmann; Otmar Pachinger; Carlo Di Mario Journal: EuroIntervention Date: 2006-05 Impact factor: 6.534
Authors: Sigmund Silber; Per Albertsson; Francisco F Avilés; Paolo G Camici; Antonio Colombo; Christian Hamm; Erik Jørgensen; Jean Marco; Jan-Erik Nordrehaug; Witold Ruzyllo; Philip Urban; Gregg W Stone; William Wijns Journal: Eur Heart J Date: 2005-03-15 Impact factor: 29.983